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ABSTRACT
Because there are few studies regarding the clinical impact of circulating EBV-
DNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBV-
DNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 
110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients 
(42.7%) showed positive results for EBV-DNA, and these patients also had stage 
III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 
0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free 
survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBV-
DNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). 
Multivariable analysis showed that poor performance status, extranodal involvement 
more than one site and positive EBV-DNA results were related with OS and PFS (P < 
0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using 
these three variables, we made a new prognostic model which classified patients on 
risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. 
The new prognostic model could stratify the three groups for OS and PFS better 
than either international prognostic index or prognostic index of PTCL-u, and showed 
statistical significance in PTCL, not otherwise specified. This study suggests that 
whole blood EBV-DNA is related with aggressive clinical characteristics and inferior 
survival. The new prognostic model, which incorporates EBV-DNA, could better stratify 
PTCL patients.
INTRODUCTION
Peripheral T-cell lymphoma (PTCL) is composed of 
15-20% aggressive lymphoma and 5-10% non-Hodgkin’s 
lymphomas (NHLs) and it is more prevalent in Asia than in 
Western countries [1]. PTCL is a group of heterogeneous 
disease with many different pathologic subtypes [2]. 
Although treatment outcome for B-cell NHL has been 
much improved, PTCL still has a dismal prognosis [3]. 
To predict the poor prognostic group of PTCL patients, 
the international prognostic index (IPI) had been widely 
used, as it has for other kinds of NHL [4]. However, IPI 
does not reflect the aggressive characteristics of PTCL, 
various kinds of scoring system such as prognostic index 
of PTCL-u (PIT) have been developed to predict survival 
in PTCL [5–7]. To improve the poor outcome of PTCL, 
it is important to stratify the broad spectrum of PTCL by 
defining the clinically usable prognostic factors.
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Epstein-Barr virus (EBV) is a member of the 
γ-herpes virus family, which is found in many healthy 
adults [8]. EBV mainly resides in B-cells as harmless 
passenger, but it can infect B-cells or other cells, and 
could be a cause of malignant lymphoma [9]. Burkitt 
lymphoma, Hodgkin lymphoma (HL) and post-transplant 
lymphoproliferative disorder (PTLD) are known to 
be EBV-related diseases, although the mechanism 
of EBV is different according to each subtype [10]. 
Recently, many studies have reported on the role of 
circulating EBV-DNA in EBV-related lymphoma. 
Unlike EBV reactivation in immunocompromised 
patients, EBV-associated tumor, such as those found 
in HL and extranodal NK/T-cell lymphoma, nasal type 
(ENKL), contain fragmented EBV-DNA from tumor in 
immunocompetent patients. Plasma EBV-DNA in HL, 
as shown by real-time quantitative polymerase chain 
reaction (RQ-PCR), could be used as a biomarker to 
predict treatment response; moreover plasma EBV-DNA 
load has been associated with negative prognosis [11, 
12]. Presence of EBV has been closely associated with 
development of ENKL, and high quantitative plasma 
EBV-DNA reflected the inferior overall survival (OS) 
in the patients with ENKL [13, 14]. Although plasma 
sample has been used in most studies, there is still 
controversy regarding which blood source could reflect 
the disease characteristics more accurately. Some studies 
have reported that whole blood EBV-DNA could also be 
a good source for predicting outcome in HL or diffuse 
large B-cell lymphoma (DLBCL) [15, 16]. Although 
EBV positivity in tumor tissue has been related 
with negative prognosis in PTCL, there are few data 
regarding the role of circulating EBV-DNA in PTCL 
[6, 17]. While serum EBV positivity has been related 
with poor progression-free survival (PFS) in PTCL, not 
otherwise specified (PTCL-NOS), it has not been shown 
to have clinical significance for predicting survival in 
multivariable analysis [18]. Moreover, quantitative 
analysis of EBV-DNA in the plasma has not been related 
with OS in PTCL [19].
In this study, we evaluated the presence of 
circulating EBV-DNA in whole blood from PTCL patients 
with respect to clinical outcome, and established a new 
prognostic model that incorporates EBV-DNA as a risk 
factor.
RESULTS
Baseline characteristics according to EBV-DNA
Median age of the 110 patients studied was 63 years 
(range, 20-94), and 65 (59.1%) were male patients. Thirty 
patients (27.3%) showed poor performance status, Eastern 
Cooperative Oncology Group (ECOG) ≥ 2. Ninety-seven 
patients (88.2%) were stage III/IV, and 37 patients (33.6%) 
had extranodal involvement more than one site. Seventy-
five patients (68.2%) had elevated lactate dehydrogenase 
(LDH) level. Bone marrow involvement was detected in 
49 patients (44.5%) among the 105 available patients. For 
IPI scores, 15 patients (13.6%) were classified as low risk, 
28 (25.5%) as low-intermediate risk, 37 (33.6%) as high-
intermediate risk, and 30 (27.3%) as high risk. For PIT 
scores among the 105 evaluable patients, 10 (9.5%) were 
assigned to group 1, 24 (22.9%) in group 2, 34 (32.4%) in 
group 3, and 37 (35.2%) in group 4. Eighty-nine patients 
(80.9%) could be evaluated for treatment response. Thirty 
patients (27.3%) achieved complete response (CR) and 28 
(25.5%) achieved partial response (PR). Three patients 
(2.7%) had stable disease and 28 (25.5%) had progressed 
disease.
Forty-seven patients (42.7%) had positive results for 
EBV-DNA in whole blood. The copy number range was 
5.4×102 - 1.9×107/mL and the median value of EBV-DNA 
was 1.73×104/mL. The positive results for EBV-DNA had 
significantly associated with stage III/IV disease, elevated 
LDH level and low albumin level (P = 0.007, P = 0.004, 
P = 0.002, respectively). Other variables did not differ 
according to EBV-DNA positivity. Both EBV-encoded 
small RNA in situ hybridization (EBER-ISH) and EBV-
DNA results were evaluable in 47 patients (39.4%); 10 
patients (21.3%) had both positive results, and 16 patients 
(34.0%) had both negative results. Eleven patients (23.4%) 
were EBV-DNA positive but EBER negative, and 10 
patients (21.3%) were EBV-DNA negative but EBER 
positive. There was no relation between EBV-DNA and 
EBER-ISH (P = 0.566). Patient characteristics according 
to EBV-DNA positivity are shown in Table 1. Treatment 
response did not differ according to EBV-DNA positivity 
(Table 1).
Influence of EBV-DNA on survival analysis
The median follow-up period was 6.5 months 
(range, 0-137 months). Median OS and PFS were 14 
months (95% confidence interval (CI), 9.8-18.1) and 
6 months (95% CI, 3.6-8.3). Fiver-year OS and PFS 
were 21.0% and 18.0%, respectively. OS and PFS were 
significantly inferior in patients with the following factors; 
poor performance status (ECOG ≥ 2) (P < 0.001 and P 
< 0.001, respectively), extranodal involvement more than 
one site (P < 0.001, P = 0.003), and albumin < 3.5 g/dL (P 
= 0.007, P = 0.022). EBER-ISH results were not related 
with OS and PFS (P = 0.186, P = 0.980). OS and PFS 
of the patients with positive EBV-DNA were 9.0 months 
(95% CI, 3.6-14.3) and 3.0 months (95% CI, 0.7-5.2) 
while those of patients with negative EBV-DNA was 17.0 
months (95% CI, 12.0–21.9) and 11.0 months (95% CI, 
7.40-14.5) (P = 0.029 and P = 0.001, respectively) (Figure 
1A, 1B).
In multivariable analysis, ECOG ≥ 2 (P < 0.001, 
P < 0.001), extranodal involvement more than one site 
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Table 1: Baseline characteristics according to Epstein-Barr virus results
Total patients
n = 110 (%)
EBV-DNA positive
n = 47 (%)
EBV-DNA negative
n = 63 (%) P value
Age 0.436
 > 60 years 63 (57.3) 30 (63.8) 35 (55.6)
 ≤ 60 years 47 (42.7) 17 (36.2) 28 (44.4)
Sex 0.171
 Male 65 (59.1) 24 (51.1) 41 (65.1)
 Female 45 (40.9) 23 (48.9) 22 (34.9)
Performance status 0.198
 ECOG 0-1 80 (72.7) 31 (34.0) 49 (77.8)
 ECOG ≥ 2 30 (27.3) 16 (66.0) 14 (22.2)
Lymphoma subtype 0.775
 PTCL, NOS 73 (66.4) 32 (68.1) 41 (65.1)
 AITL 22 (20.0) 10 (21.3) 12 (19.0)
 Others 15 (13.6)  5 (10.6) 10 (15.9)
B symptoms 0.324
 Negative 56 (53.8) 22 (47.8) 34 (58.6)
 Positive 48 (46.2) 24 (52.2) 24 (41.4)
Stage 0.007
 Stage I/II 13 (11.8) 1 (2.0) 12 (19.0)
 Stage III/IV 97 (88.2) 46 (98.0) 51 (81.0)
Extranodal sites 0.999
 0-1 73 (66.4) 31 (66.0) 42 (66.7)
 ≥ 2 37 (33.6) 16 (34.0) 21 (33.3)
Lactic dehydrogenase 0.004
 Normal 35 (31.8)  8 (17.0) 27 (42.9)
 Elevated 75 (68.2) 39 (83.0) 36 (57.1)
Bone marrow involvement 0.234
 Negative 56 (53.3) 20 (45.5) 36 (59.0)
 Positive 49 (46.7) 24 (54.5) 25 (41.0)
IPI at diagnosis  0.114
 Low/Low-intermediate 43 (39.1) 14 (29.8) 29 (46.0)
 High-intermediate/High 67 (60.9) 33 (70.2) 34 (54.0)
PIT at diagnosis 0.207
 Group 1/2 34 (32.4) 11 (25.0) 23 (37.7)
 Group 3/4 71 (67.6) 35 (75.0) 38 (62.3)
Response 0.247
 CR/PR 58 (65.2) 18 (56.3) 40 (70.2)
(Continued )
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(P < 0.001, P = 0.001) and positive EBV-DNA (P = 
0.011, P = 0.001) were related with inferior OS and PFS 
(Table 2). The new scoring system incorporated these 
three factors, assigning one point to each factor (ECOG 
≥ 2, extranodal involvement more than one site, positive 
EBV-DNA), and patients were classified as follows; low 
risk, no adverse factors; intermediate risk, presence of 
one factor; high risk, presence of two or more factors. As 
a result, 34 patients (30.9%) were designated as low risk, 
47 (42.7%) as intermediate risk, and 29 (26.4%) patients 
as high-risk.
Comparison of three prognostic models
We compared three prognostic scoring system, 
assessed by statistical method. Although IPI could identify 
OS and PFS for patients at all risk factor levels (P = 0.001, 
P = 0.042), it could not discriminate between low risk and 
Total patients
n = 110 (%)
EBV-DNA positive
n = 47 (%)
EBV-DNA negative
n = 63 (%) P value
 SD/PD 31 (34.8) 14 (43.8) 17 (29.8)  
ALC 0.557
 ≥ 1,000 66 (60.0) 30 (63.8) 36 (57.1)
 < 1,000 44 (40.0) 17 (38.2) 27 (42.9)
Albumin 0.004
 ≥ 3.5 58 (52.7) 17 (36.2) 41 (65.1)
 < 3.5 52 (47.3) 30 (63.8) 22 (34.9)
Ferritin 0.796
 > 1,000 18 (17.5)  9 (19.1)  9 (16.1)
 ≤ 1,000 85 (82.5) 38 (80.9) 47 (83.9)
EBER-ISH 0.766
 Negative 27 (58.7) 11 (55.0) 16 (61.5)
 Positive 19 (41.3)  9 (45.0) 10 (38.5)
Abbreviations: EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; PTCL, NOS, peripheral T-cell 
lymphoma, not otherwise specified; AITL, Angioimmunoblastic T-cell lymphoma; IPI, International Prognostic Index; PIT 
Prognostic Index for PTCL-u; CR, Complete response; PR, Partial response; SD, Stable disease; PD, progressive disease; 
ALC, Absolute lymphocyte count; EBER-ISH, EBV-encoded small RNAs-in situ hybridization.
Figure 1: Overall survival (A) and progression free survival (B) according to EBV-DNA positivity. 
Oncotarget92316www.impactjournals.com/oncotarget
low-intermediate risk (P = 0.081, P = 0.066), or between 
low-intermediate and high-intermediate risk patients 
(P = 0.051, P = 0.999) (Figure 2A, 2B). PIT could not 
discriminate the patients for OS and PFS for patients at all 
factor levels (P = 0.095, P = 0.684) (Figure 2C, 2D). Five-
year OS and PFS of each prognostic model were shown in 
Table 3. The new prognostic model could identify different 
OS and PFS according to risk group (P < 0.001, P < 0.001) 
(Figure 3A, 3B), and it also showed statistical significance 
in the patients with PTCL, NOS (P < 0.001, P < 0.001) 
(Figure 3C, 3D). Akaike information criterion (AIC) value 
was lowest in the new prognostic model for predicting OS 
and PFS (AIC OS; 451.722, AIC PFS; 460.319) compared 
to IPI (AIC OS; 472.698, AIC PFS; 484.787) or PIT (AIC 
OS; 477.919, AIC PFS; 489.256) (Table 4). The new 
prognostic model showed better discrimination ability 
for OS and PFS than did either IPI or PIT, as shown by 
linear trend χ2 test (new prognostic model - linear trend 
χ2 test for OS; 24.63 and PFS; 24.17). Harrel’s c index 
was calculated to evaluate predictive ability, and the new 
prognostic model showed the highest scores for predicting 
OS and PFS among the three prognostic scoring system.
DISCUSSION
This study demonstrated that circulating EBV-DNA 
in whole blood were detected in about 40% of the newly 
diagnosed PTCL patients, and positive EBV-DNA results 
were related with aggressive clinical features and inferior 
OS and PFS. The new prognostic model, which was 
composed of three factors including positive circulating 
EBV-DNA, poor performance status (ECOG ≥ 2) and 
extranodal involvement more than one site, based on 
multivariable analysis, was shown to be more predictive 
for OS and PFS than was either IPI or PIT.
To date, the role of circulating EBV-DNA in 
lymphoma has been mostly evaluated in ENKL or HL. 
High EBV-DNA load in plasma was related with advanced 
stage and elevated LDH level, the patients with high EBV-
DNA level were refractory to treatment and had inferior 
survival in ENKL [13, 14]. Plasma EBV-DNA has been 
recognized as an important prognostic factor to predict 
treatment response or survival in HL [11, 12]. On the 
other hand, the role of circulating EBV-DNA in PTCL 
Table 2: Univariable and multivariable analyses for overall survival and progression-free survival
OS PFS
HR (95% CI) P value HR (95% CI) P value
Univariable analysis
 Age > 60 years 1.12 (0.68-1.85) 0.651 0.91 (0.58-1.43) 0.688
 Male sex 0.84 (0.51-1.37) 0.488 0.97 (0.62-1.53) 0.917
 ECOG ≥ 2 3.03 (1.78-5.14) < 0.001 2.59 (1.57-4.28) < 0.001
 Stage III/IV 1.61 (0.69-3.78) 0.266 2.20 (0.95-5.09) 0.065
 Extranodal involvement > 1 2.46 (1.50-4.03) < 0.001 2.01 (1.27-3.17) 0.003
 Elevated LDH 1.82 (1.04-3.18) 0.034 1.39 (0.85-2.27) 0.183
 Bone marrow involvement 1.56 (0.94-2.60) 0.083 1.34 (0.84-2.12) 0.214
 Albumin < 3.5 g/dL 2.07 (1.26-3.40) 0.004 1.69 (1.07-2.65) 0.022
 ALC < 1,000/μL 1.40 (0.84-2.32) 0.189 1.24 (0.78-1.96) 0.352
 Ferritin > 1,000 1.36 (0.70-2.63) 0.355 1.41 (0.77-2.58) 0.257
 EBER-ISH, positive 0.55 (0.20-1.48) 0.240 0.99 (0.46-2.09) 0.980
 EBV-DNA, positive 1.79 (1.09-2.95) 0.021 2.05 (1.30-3.25) 0.002
Multivariable analysis
 ECOG ≥ 2 3.26 (1.89-5.64) < 0.001 2.46 (1.48-4.08) 0.001
 Extranodal involvement > 1 2.60 (1.58-4.29) < 0.001 2.06 (1.30-3.26) 0.002
 EBV-DNA, positive 2.01 (1.20-3.34) 0.007 2.27 (1.43-3.61) < 0.001
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, 
Eastern Cooperative Oncology Group; LDH, lactic dehydrogenase; ALC, absolute lymphocyte count; EBER-ISH, EBV-
encoded small RNAs-in situ hybridization; CR, complete response; EBV, Epstein-Barr virus.
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has not been fully elucidated, although a few studies 
have reported the negative prognostic impact of EBER-
ISH in T-cell lymphoma [17, 20, 21]. Based on gene 
expression profile data, EBER-ISH positive results in 
PTCL-NOS were related with fatal outcomes, and these 
patients expressed the immune response related gene [22]. 
Yang et al. showed that EBV-infected T-cells expressed 
higher levels of cytokine, IL-9, which suggested that EBV 
could affect the pathogenesis of EBV-associated T-cell 
disease [23]. Among PTCL, EBV infected B-cell clones 
were detected in AITL. These findings may distinguish 
AITL from other subtypes of PTCL [24, 25]. Therefore, 
EBV infection may play a role in development of PTCL. 
According to the recently revised WHO classification, 
node-based EBV+ PTCL was defined as nodal disease of 
PTCL-NOS with EBV positive in tumor cells [26, 27]. 
These findings suggested that EBV infection-associated 
PTCL could be considered as a distinct subgroup in PTCL. 
However, few studies have evaluated the role of EBV-
DNA in PTCL. Two previous studies showed that positive 
EBV results in both serum and plasma were not related 
with clinical outcome in PTCL [18, 19]. However, those 
studies enrolled a small number of patients or used serum 
viral capsid antigen or early antigen tests. In this study, we 
tried to investigate the role of EBV-DNA in whole blood.
According to our data, EBV-DNA in whole blood 
was detected in 42.7% of PTCL patients and positive 
circulating EBV-DNA was related with advanced stage, 
elevated LDH level and low albumin level. Because 
stage and serum LDH level were related with tumor 
burden, positive whole blood EBV-DNA may be related 
with large tumor burden. In addition, low albumin level 
which was already known to be an important prognostic 
factor in PTCL [28, 29] showed a significant correlation 
with positive whole blood EBV-DNA. In our study, the 
proportion of patients with EBV-DNA positive results was 
not different according to age. This finding suggested that 
positive EBV-DNA in whole blood could not regarded as 
the abnormality associated only with age-related factor. 
For elderly patients with reduced the immune surveillance 
and vulnerability to EBV infection, it could be a cause of 
malignant lymphoma. However, we did not find a clear 
Figure 2: Overall survival (OS) and progression free survival (PFS) according to international prognostic index (IPI) 
and to prognostic index for PTCLu (PIT). (A) OS of IPI, (B) PFS of IPI (C) OS of PIT (D) PFS of PIT. The tables within the figure 
show the P-value between each factor by log-rank test. Abbreviations: L; Low, LI; low- intermediate, HI; high-intermediate, H; high.
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Table 3: Comparison of survival between IPI, PIT and the new model
N (%) 5-year OS(%) P value 5-year PFS(%) P value
IPI 0.001 0.042
 Low risk 15 (13.6) 53.0 37.0
 Low-intermediate risk 28 (25.5) 23.0 17.0
 High-intermediate risk 37 (33.6) 18.0 17.0
 High risk 30 (27.3) 8.0 8.0
PIT 0.095 0.684
 Group 1 10 (9.5) 43.0 22.0
 Group 2 24 (22.9) 36.0 20.0
 Group 3 34 (32.4) 16.0 16.0
 Group 4 37 (35.2) 19.0 15.0
New model < 0.001 < 0.001
 Low risk 34 (30.9) 41.0 33.0
 Intermediate risk 47 (42.7) 17.0 12.0
 High risk 29 (26.4) 7.0 9.0
Abbreviations: IPI, International Prognostic Index; PIT, prognostic index for PTCLu; OS, overall survival; PFS, 
progression free survival.
Figure 3: Overall survival (OS) and progression free survival (PFS) according to the new prognostic model. The tables 
within the figure show the comparison between each factor by log-rank test. (A) OS, (B) PFS of the new prognostic model, 
(C) OS, (D) PFS of new prognostic model in peripheral T-cell lymphoma, NOS (PTCL, NOS). The tables within figure show the P-value 
between each factor by log-rank test.
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correlation between circulating EBV-DNA and age in 
PTCL patients. As in previous study, there was no clear 
relation between circulating EBV-DNA and EBER-ISH, 
and positive EBV-DNA results did not reflect the EBER 
status in tumor tissue [12, 15], thus circulating EBV-
DNA is more predictive of clinical outcome than EBER 
status. In this study, the patients with positive EBV-DNA 
showed inferior OS and PFS as compared to those patients 
with negative EBV-DNA. Therefore, it is necessary to 
investigate the exact role of EBV for the progression of 
PTCL and develop EBV-specific therapeutic strategies for 
the PTCL patients with positive EBV-DNA.
We chose three variables showing significance based 
on multivariable analysis, including circulating EBV-
DNA, performance status, and extranodal involvement 
more than one site, and we suggested the new prognostic 
model. The new scoring system showed the most statistical 
significance as compared to IPI or PIT. Although IPI has 
been widely used like other kinds of NHLs, it could not 
reflect the aggressive clinical characteristics of PTCL, thus 
PIT including bone marrow involvement was suggested 
[7]. However, IPI could not differentiate the patients 
between the low and low-intermediate, or between low-
intermediate and high-intermediate risk group for OS and 
PFS. PIT also could not identify each group to different 
outcome in our cohort. On the contrary, the new prognostic 
model incorporating EBV-DNA results could stratify 
the PTCL patients well, and it also showed statistical 
significance for the patents with PTCL, NOS. The new 
prognostic model showed the lowest AIC, it indicated a 
more suitable to predict the OS and PFS, and the highest 
linear trend χ2 test and Harrell’s c index among the three 
models, suggesting that it has the best discriminatory 
ability and predictive accuracy [30, 31].
There has been still some argument about the best 
blood source for detecting EBV-DNA. Most studies 
emphasized that pretreatment EBV-DNA in plasma is related 
with treatment response and survival, because plasma EBV 
DNA reflects the tumor burden [12, 13]. However, it has a 
short half-life with several minutes, and the samples are hard 
to handle. In contrast, EBV quantitation in whole blood can 
detect EBV-DNA presented in both the cellular component 
and cell-free compartment. The EBV-DNA level in whole 
blood is usually higher than in plasma. Therefore, EBV-
DNA assay using whole blood is relatively easy to detect and 
easy to handle [32, 33]. Recent studies showed that EBV-
DNA in whole blood was useful for predicting the clinical 
outcome in HL or DLBCL [15, 16]. In relapsed/refractory 
ENKL, EBV-DNA in whole blood is a more sensitive 
marker than plasma EBV-DNA in predicting response or 
adverse events of SMILE (steroid, methotrexate, ifosfamide, 
L-asparaginase, and etoposide) chemotherapy [34]. Although 
we did not detect the circulating tumor cells in this study, it 
was possible to detect circulating tumor cells in patients with 
bone marrow involvement. In this study, proportion of the 
patients with bone marrow involvement was not different 
according to the positivity of EBV-DNA. Therefore, it is 
not possible to conclude that EBV-DNA in whole blood 
is only related with circulating tumor cells. Similarly, 
previous study reported that the ENKL patients with EBV-
DNA positive in whole blood did not related with the 
leukemic presentation [34]. To reveal the exact mechanism 
of detecting EBV-DNA in whole blood, it is necessary to 
analyze the DNA fragment lengths, and compare the EBV-
Table 4: Comparison of prediction power between IPI, PIT and the new prognostic model
IPI PIT New model
OS
 Goodness of fit (AIC) 472.698 477.919 451.722
 Discriminatory ability
 (Linear Trend χ2 test) 10.55 6.19 24.63
 Predictive ability
 (Harrell’s c index) 0.667 0.638 0.715
PFS
 Goodness of fit (AIC) 484.787 489.256 460.319
 Discriminatory ability
 (Linear Trend χ2 test) 3.46 1.54 24.17
 Predictive ability
 (Harrell’s c index) 0.601 0.577 0.702
Abbreviations: IPI, International Prognostic Index; PIT, prognostic index for PTCLu; OS, overall survival; PFS, 
progression free survival; AIC, Akaike information criterion.
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DNA level between whole blood and plasma. We evaluated 
all PTCL patients with immunocompetent status to exclude 
the tumorigenesis rising from EBV reactivation in patients 
with immunocompromised status such as PTLD or human 
immunodeficiency virus (HIV)-associated lymphoma. 
Although there are concerns that the detection of EBV-
DNA using whole blood could not discriminate the viral 
load from tumor cell or latently infected benign B-cells [35], 
EBV-DNA level in whole blood might reflect actual clinical 
situations, because it includes both cellular and plasma 
component [33, 36].
This study has some limitations. First, it was 
composed of many heterogeneous subgroups of PTCL 
patients and performed in single center, retrospectively. 
To improve these limitations, we included the all 
consecutive patients who were diagnosed with PTCL 
in our institution. Second, both EBER-ISH and EBV-
DNA results were evaluable in only 47 patients (39.4%), 
because EBER-ISH was not a test routinely given upon 
diagnosis of PTCL, thus our results did not exactly reflect 
the association between EBER-ISH and circulating EBV-
DNA in whole blood. However, this study did provide 
statistically powerful values using AIC, linear trend χ2 
test and Harrell’s c index. To reveal the clinical impact 
and meaning of EBV-DNA in PTCL, it will be needed to 
validate data in a large population prospective study, with 
monitoring of serial follow ups.
This study suggests that patients with pretreatment 
positive EBV-DNA results in whole blood are related with 
aggressive clinical features and inferior OS and PFS. The 
new prognostic model composed of positive EBV-DNA, 
poor performance status, and extranodal involvement more 
than one site, is more suitable for predicting outcomes for 
PTCL than are either IPI or PIT.
MATERIALS AND METHODS
Patients
Between January 2002 and December 2015, 
2,409 patients were newly diagnosed with lymphoma 
at Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea. Among these patients, we 
retrospectively evaluated the 259 (10.8%) patients who 
were diagnosed PTCL. Histology was confirmed by 
hematopathology specialists. We excluded 85 patients who 
had different clinical characteristics compared to PTCL; 
ENKL, primary cutaneous T-cell lymphoma, anaplastic 
large-cell lymphoma (ALCL)-anaplastic lymphoma kinase 
(ALK) positive, precursor T-lymphoblastic leukemia/
lymphoma, HIV-associated lymphoma or PTLD.
In total, 110 PTCL patients were included in this 
study, 73 (66.4%) with PTCL, NOS, 22 (20.0%) with 
angioimmunoblastic T-cell lymphoma, 12 (10.9%) with 
ALCL-ALK negative, and 3 (2.7%) with enteropathy-
associated T-cell lymphoma. All patients had whole 
blood EBV-DNA results before starting chemotherapy. 
One hundred patients (90.9%) were treated with first 
line chemotherapy while the other 10 patients could not 
receive chemotherapy due to poor performance status or 
infection (Supplementary Table 1). Response to treatment 
was assessment by using international workshop response 
criteria [37, 38]. We excluded patients who received 
upfront autologous hematopoietic stem cell transplantation 
(ASCT) because upfront ASCT could be a standard 
therapeutic option only for young and chemo-sensitive 
patients and upfront ASCT may improve the treatment 
outcomes.
Prognostic index
IPI scores were based on age, ECOG performance 
status, LDH level, the number of extranodal sites 
involvement and Ann Arbor stage [4]. Four risk groups 
were defined based on IPI scores: 0 to 1, low risk; 2, low-
intermediate risk; 3, high-intermediate risk; and 4 to 5, 
high risk. PIT was scored by age, ECOG performance 
status, LDH level, and bone marrow involvement. The 
four risk groups were defined by PIT scores: 0, group 1; 1, 
group 2; 2, group 3; and 3 to 4, group 4 [7].
RQ-PCR of EBV-DNA
EBV-DNA was isolated from whole blood samples 
by manual extraction using QIAamp DNA Blood Mini 
Kits (QIAGEN Inc., Valencia, CA, USA). Quantitative 
real-time PCR (RealArt EBV LC PCR kit, Qiagen, 
Hamburg, Germany) was performed using a LightCycler 
2.0 (Roche Molecular Diagnostics, Pleasanton, CA, 
USA). Thermal cycling was initiated at 50°C for 1 
minute, followed by a first denaturation step of 95°C for 
10 minutes, and then 45 cycles of 95°C for 15 seconds 
and 50°C for 1 minute. Results are expressed in copies/ml 
of total EBV-DNA calculated using a standard curve. The 
lowest detection limit of EBV-DNA in whole blood was 
510 copies/mL.
In situ hybridization for EBV
ISH analysis of EBER was performed for detection of 
latent EBV infection in paraffin-embedded tissue sections, 
according to the supplier’s instructions (Novocastra, 
Newcastle upon Tyne, United Kingdom). Paraffin sections 
were dewaxed in xylene and hydrated through graded 
alcohols and distilled water. The slides were then treated 
with proteinase K (10 μg/mL, Dako) at 37°C for 15 
minutes and washed in Tris-buffered saline (50 mmol/L 
Tris-HCl, 150 mmol/L NaCl; pH = 7.6) containing 0.1% 
Triton X-100. The slides were incubated with fluorescein-
conjugated EBER probes (Novocastra) while covered with 
cover glasses at 37°C for 120 minutes. The slides were then 
washed in Tris-buffered saline followed by a washing with 
a stringent wash solution at 45°C for 20 minutes. After 
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being washed, the slides were incubated with an alkaline 
phosphatase-conjugated antifluorescein isothiocyanate 
antibody (Novocastra) for 30 minutes, and then washed in 
Tris-buffered saline. Next, signals were detected by using 
a BCIP/NBT chromogen kit (Dako), and the sections were 
counterstained with nuclear fast red. Positive and negative 
control slides were processed in parallel.
Statistical analysis
The statistical significance of categorical variables 
was examined using Fisher’s exact tests. Survival curves 
were estimated using the Kaplan-Meier test and survival 
difference was evaluated using the log-rank test. OS 
was measured from the date of diagnosis until death 
from any cause, and surviving patients were censored at 
the last follow-up date. PFS was defined from the date 
of diagnosis to the date of disease progression, relapse, 
or death from any cause. To rule out multicollinearity 
between the included parameters, variance inflation 
factor (VIF) was assessed. VIF values were checked for 
the independent variables included in the multivariable 
model. VIF values ranged from 1.08 to 1.35, indicating 
the absence of multicollinearity (Supplementary Table 2).
We calculated the AIC, for each prognostic score 
to demonstrate which score was more explanatory and 
informative in predicting survival. The AIC is a commonly 
used measure for comparing competing models, and a 
smaller AIC indicates the preferred model [30]. Lastly, 
the time-dependent receiver operating characteristic curve 
method was used to compare the three prognostic models 
on predictive accuracy for OS or PFS over the entire range 
of follow-up times [31]. A P-value < 0.05 was considered 
statistically significant for all analyses. All statistical 
analyses were performed using SPSS for Windows, 
version 20.0 (IBM Corp., Armonk, NY, USA).
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